Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 21;53(2):314–320. doi: 10.1111/apt.16172

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

(A) Hepatitis B surface antigen (HBsAg) decline during treatment and follow‐up in patients with an hepatitis B virus (HBV) RNA response at on‐treatment week 24, stratified by patients with and without sustained response (HBV DNA <2000 IU/mL; SR). (B) Hepatitis B core‐related antigen (HBcrAg) decline during treatment and follow‐up in patients with an HBV RNA response at on‐treatment week 24, stratified by patients with and without SR. Assessed in patients with positive hepatitis B e antigen (HBeAg) at baseline. P‐value for comparison at week 24. BL, baseline; EOF, end of follow‐up; EOT, end of treatment; HBcrAg, hepatitis B core‐related antigen; HBsAg, hepatitis B surface antigen; SR, sustained response; wk, week